Chonluten is a peptide that, to date, has only been examined in preclinical mechanistic research confined to animal models, with zero human trials reported and no established community dosing or cycling schedule. Those who choose to use it in humans typically do so off‑label, compounding whatever dose they deem appropriate without any established protocol, because there is no FDA‑approved indication for Chonluten. The single clear limitation is the complete absence of regulatory approval, meaning any human administration is unregulated, unsupported by clinical evidence, and entirely off‑label.
Data last updated
Measured on 5 of 6 axes
Evidence shape
No CT.gov-registered trials for Chonluten, but 2 published human studies were extracted from the literature — peer-reviewed reports below, split into treatment vs diagnostic/mechanistic, not registry-grade evidence. Off-label / exploratory data exists for 1 additional indication (Treatment studies).
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Treatment studies
2 studies
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 1 out-of-stock offer not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How CHONLUTEN is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
In the two human studies identified for CHONLUTEN, no specific dosing amount, frequency, or cycle was reliably extracted. The available reports focused on clinical and biomarker outcomes rather than regimen details.
No structured protocol details captured for this tier yet.
One community user reported 2 mg daily, another used 2 mg without a stated frequency, and a third used 10‑20 mg also without a stated frequency; no cycling pattern was mentioned.